Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × ixazomib × Clear all
NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Columbia University

Phase 1 Withdrawn
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡